Amega Biotech has fully integrated its development and production operations, controlling the process all the way from the selection of the clones to the production of the purified protein according to Good Manufacturing Practices (GMP) and the formulation of the finished product. This strategy allows Amega Biotech to offer to its customers the guarantee of the origin and consistent quality of its products.

Amega Biotech is prepared to face the challenges of the upcoming biogenerics market.

Development
· Development, production, purification, characterization and testing of human cytokines grown in serum-free mediums for therapeutic use
· Generation of Master Cell Bank from single cell derived clones
· Development of proprietary technologies for sustained-release biopharmaceuticals
· Development of monoclonal antibodies

Production
· State-of-the-art manufacturing plant according to cGMP standards
· High-end facility: from the MCB (Master Cell Bank) and WCB (Working Cell Bank) generation to API production
· Internationally audited production site

Fill-finishing
· Established network of partners with cGMP approved facilities allowing access to world markets
· Guaranteed fill-finishing quality

Promotion and Distribution
· World market penetration through local distributors
· Careful selection of potential distributors to create long standing partnerships
· Marketing support